NCT05758597View on ClinicalTrials.gov

Sedative Effect and Safety of Remimazolam Besylate in ARDS Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

June 16, 2025

Conditions
Respiratory Distress Syndrome
Interventions
DRUG

Remazolam besylate

Remazolam benzoate group was given 0.1-1mg/kg/h, and the target RASS score was maintained.

DRUG

midazolam

Meanwhile the midazolam group was given 0.05-0.2 mg/kg/h midazolam, and the target RASS score was maintained.

Trial Locations (1)

250014

RECRUITING

Department of Intensive Care Medicine, Jinan

All Listed Sponsors
lead

Zhiming Jiang

OTHER